Tarter Krinsky & Drogin’s China Desk assists U.S. and Chinese companies and investors entering or operating in the U.S. and in China. From emerging businesses to global corporations, our clients do business in a variety of industries including the life sciences, chemical, products, food and beverage.
Our goal is a successful, long-term relationship. We work closely with you to understand your legal and business issues. With fifteen distinct practice areas, we can provide comprehensive solutions and guide you through all aspects of complex global transactions from licensing issues and outsourcing to regulatory requirements, intellectual property issues and leasing.
Working with trusted local counsel, our attorneys seamlessly navigate between Chinese and American culture to provide you service in both the U.S. and in China.
Our services include:
• General corporate matters
• Mergers and acquisitions and joint ventures
• Intellectual property including transactions, litigation and the Hatch Waxman process
• Real estate and construction
• Product sales and distribution
• Retail alliances and endorsements
• Licensing and franchising
• Labor and Employment
• Regulatory Issues
• E-commerce and Internet law
|Braginsky, Philip Partner||Partner||212.216.8065|
|Gaynor, Alan S. Partner||Partner||212.216.1136|
|Lin, Rachel J. Counsel||Counsel||212.216.1152|
|Rosenberg, Mark J. Partner||Partner||212.216.1127|
|Shravah, Aasheesh Counsel||Counsel||212.216.1132|
|Xia, Jing Counsel||Counsel||212.216.1158|
In December 2016, the FDA published an industry guidance related to the Biologics Price Competition and Innovation Act. This guidance offers suggestions to sponsors on the design and use of clinical pharmacology studies to support a claim of biosimilarity to a reference product.
Over the past two years, owners of U.S. patents have used Chinese companies' appearances at a trade show as a patent infringement "trap."